{"id":2280,"date":"2023-06-25T17:55:36","date_gmt":"2023-06-25T17:55:36","guid":{"rendered":"https:\/\/kidneydiseaseclinic.net\/kdc\/vincristine-sulphate\/"},"modified":"2023-06-25T17:59:57","modified_gmt":"2023-06-25T17:59:57","slug":"vincristine-sulphate","status":"publish","type":"post","link":"https:\/\/kidneydiseaseclinic.net\/kdc\/vincristine-sulphate\/","title":{"rendered":"vincristine sulphate"},"content":{"rendered":"<p><img decoding=\"async\" src=\"https:\/\/kidneydiseaseclinic.net\/renaldrugs\/img\/vincristine sulphate.JPG\"><\/p>\n<h3>  CLINICAL USE<\/h3>\n<p>Antineoplastic agent<\/p>\n<h3> DOSE IN NORMAL RENAL FUNCTION<\/h3>\n<p>IV: 1.4\u20131.5 mg\/m2 weekly; maximum 2 mg Consult relevant local protocol<\/p>\n<h3>  PHARMACOKINETICS<\/h3>\n<li> Molecular weight &nbsp;  &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;  &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; : 923<\/li>\n<li>  %Protein binding  &nbsp; &nbsp; &nbsp;  &nbsp;  &nbsp;  &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; : 75<\/li>\n<li>  %Excreted unchanged in urine &nbsp; &nbsp; :<\/li>\n<li> 10 to 20  &nbsp; &nbsp; :<\/li>\n<li> Volume of distribution (L\/kg) &nbsp; &nbsp; &nbsp; : 5\u201311<\/li>\n<li>half-life \u2013 normal\/ESRD (hrs)&nbsp; &nbsp; &nbsp; : 15\u2013155\/Unchanged<br \/>\n<h3>  DOSE IN RENAL IMPAIRMENT<\/h3>\n<h4>GFR (mL\/MIN)<\/h4>\n<\/li>\n<li> 20 to 50  &nbsp; &nbsp; : Dose as in normal renal function<\/li>\n<li> 10 to 20  &nbsp; &nbsp; : Dose as in normal renal function<\/li>\n<li> &lt;10 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; : Dose as in normal renal function<br \/>\n<h3> DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES<\/h3>\n<\/li>\n<li> CAPD  &nbsp; &nbsp; &nbsp;  &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;: Unlikely to be dialysed. Dose as in normal renal function<\/li>\n<li> HD &nbsp;  &nbsp; &nbsp;  &nbsp; &nbsp;  &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; : Unlikely to be dialysed. Dose as in normal renal function<\/li>\n<li>HDF\/high flux  &nbsp; : Unknown dialysability. Dose as in normal renal function<\/li>\n<li>CAV\/VVHD  &nbsp; &nbsp; &nbsp;: Unlikely to be dialysed. Dose as in normal renal function<br \/>\n<h3> IMPORTANT DRUG INTERACTIONS<\/h3>\n<p>Potentially hazardous interactions with other drugs<\/li>\n<li>Anti-epileptics: phenytoin levels may be   reduced<\/li>\n<li>  Antifungals: metabolism possibly inhibited   by itraconazole and posaconazole (increased risk of neurotoxicity)<\/li>\n<li>Antipsychotics: avoid concomitant   use with clozapine (increased risk of agranulocytosis)<br \/>\n<h3> ADMINISTRATION<\/h3>\n<h4> Reconstition<\/h4>\n<p>\u2013<\/p>\n<h4>  Route<\/h4>\n<p>IV<\/p>\n<h4>  Rate of Administration<\/h4>\n<p>Slow bolus<\/p>\n<h4>Comments<\/h4>\n<p>May be administered into fast running   drip of sodium chloride 0.9% or glucose 5%<\/p>\n<h4>  OTHER INFORMATION<\/h4>\n<p>Most of an IV dose is excreted into the bile   after rapid tissue binding Metabolised by cytochrome P450 (in   the CYP 3A subfamily). Elimination is primarily biliary; excreted into bile and faeces (67% within 72 hours, 40\u201350% as metabolites), 10% excreted in urine in 24 hrs<\/li>\n","protected":false},"excerpt":{"rendered":"<p>CLINICAL USE Antineoplastic agent DOSE IN NORMAL RENAL FUNCTION IV:<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[7],"class_list":["post-2280","post","type-post","status-publish","format-standard","hentry","category-blog","tag-post-by-auto-php"],"_links":{"self":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/2280","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/comments?post=2280"}],"version-history":[{"count":1,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/2280\/revisions"}],"predecessor-version":[{"id":2301,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/2280\/revisions\/2301"}],"wp:attachment":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/media?parent=2280"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/categories?post=2280"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/tags?post=2280"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}